Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Medicines for Malaria Venture: steps towards eliminating a global scourge

With the US approval of MMV and GSK’s Krintafel (tafenoquine), a single-dose treatment for recurring malaria, the pharmaceutical industry has come one step closer to eliminating malaria. MMV’s CEO David Reddy explains the process of developing the drug with GSK, how it works and what further challenges face the industry in its quest to fully eradicate malaria.

Close
Close
Close

Go Top